Viewing details of messages, sorted by time of last reply ("sticky messages" first)
Vitamin D May promote Brain Health
Vitamin D May promote Brain Health
Low blood levels of Vitamin D may increase the risk of dementia and Alzheimer’s Disease, according to a new hypothesis based on existing risk factors.
A growing number of studies have linked deficiency of Vitamin D to increased risks of Cardiovascular Disease, Diabetes, Osteoporosis, Depression, and even Periodontal Disease, all of which have been linked to some degree to increased risks for Dementia.
A recent study reported that as many as 90 percent of 50 to 70 year olds may be Vitamin D deficient or insufficient, with similar findings being reported in Western Populations.
“To date, the evidence includes observational studies supporting a beneficial role of Vitamin D in reducing the risk of diseases linked to Dementia such as vascular and metabolic diseases, as well as an understanding of the role of Vitamin D in reducing the risk of several mechanisms that lead to Dementia.” This according to William Grant PhD of “SUNARC” Research
Low blood levels of Vitamin D may increase the risk of dementia and Alzheimer’s Disease, according to a new hypothesis based on existing risk factors.
A growing number of studies have linked deficiency of Vitamin D to increased risks of Cardiovascular Disease, Diabetes, Osteoporosis, Depression, and even Periodontal Disease, all of which have been linked to some degree to increased risks for Dementia.
A recent study reported that as many as 90 percent of 50 to 70 year olds may be Vitamin D deficient or insufficient, with similar findings being reported in Western Populations.
“To date, the evidence includes observational studies supporting a beneficial role of Vitamin D in reducing the risk of diseases linked to Dementia such as vascular and metabolic diseases, as well as an understanding of the role of Vitamin D in reducing the risk of several mechanisms that lead to Dementia.” This according to William Grant PhD of “SUNARC” Research
Good news for Alzheimer's disease patients.
Good news for Alzheimer's disease patients. A recently published randomized, double-blind, placebo-controlled, multicenter trial (http://www.nutritionand metabolism.com/content/6/1/31) indicates butyrate derivatives improve cognitive functions.... COMMENTS from the Longevity Institute: Butyric acid is a short chain fatty acid present only in butter and absent in vegetable oil (http://www.longevinst.org/longevinst. org/data1.htm) - The suppression of butter and its replacement by vegetable oil may well have been a factor in the spread of Alzheimer's disease (http://www.longevinst.org/longevinst. org/nlt/alzheimer.htm).
Doctors debate optimal vitamin D levels
Doctors debate optimal vitamin D levels, however most agree, most people need more
The Standing Committee of European Doctors (CPME) is preparing a vitamin D policy paper it hopes can influence European national associations considering vitamin D medical recommendations.
“The development of their policy paper is a shift from the existing nutrition recommendations and will be of real added value in convincing politicians of the need for action – this mirrors to an extent the ongoing efforts in the United States.” Said David Webber, the director of studies at PA International Foundation.”
“While scientists continue to discuss and disagree on the optimum levels and recommendations of vitamin D, there is clearly a case of need to start somewhere – especially since recent studies again demonstrate widespread deficiencies in many parts of society,” This according to David Webber, Director of studies at PA International Foundation.
The Standing Committee of European Doctors (CPME) is preparing a vitamin D policy paper it hopes can influence European national associations considering vitamin D medical recommendations.
“The development of their policy paper is a shift from the existing nutrition recommendations and will be of real added value in convincing politicians of the need for action – this mirrors to an extent the ongoing efforts in the United States.” Said David Webber, the director of studies at PA International Foundation.”
“While scientists continue to discuss and disagree on the optimum levels and recommendations of vitamin D, there is clearly a case of need to start somewhere – especially since recent studies again demonstrate widespread deficiencies in many parts of society,” This according to David Webber, Director of studies at PA International Foundation.
Vitamin D May be the Vitamin for Cold and Flu Seas
Vitamin D May be the Vitamin for Cold and Flu Season
According to findings of a study with about 19,000 adults and adolescents, people with the lowest average levels of Vitamin D were about 40% more likely to have a recent respiratory infection, compared to those with higher Vitamin D levels.
The findings, published in this week’s Archives of Internal Medicine, indicated that increased intakes of the sunshine vitamin may be an important way to prime the immune system against disorders like the common cold.
“To our knowledge, this is the first population-based study to evaluate and demonstrate an association between serum 25 (OH) D level and upper respiratory tract infections,” wrote lead author of the study, Adit Ginde, MD from the University of Colorado, Denver.
For a Superior Vitamin D supplement ask me about Suzanne Sommers "Sip of Sunshine," Also contains Vitamin D3, Selenium, Patented GliSODin®, as well as Secalate™, Flower Pollen Extract-G40, Progallate™, Green Tea Extract (containing 50% EGCG) and B Vitamin Complex
According to findings of a study with about 19,000 adults and adolescents, people with the lowest average levels of Vitamin D were about 40% more likely to have a recent respiratory infection, compared to those with higher Vitamin D levels.
The findings, published in this week’s Archives of Internal Medicine, indicated that increased intakes of the sunshine vitamin may be an important way to prime the immune system against disorders like the common cold.
“To our knowledge, this is the first population-based study to evaluate and demonstrate an association between serum 25 (OH) D level and upper respiratory tract infections,” wrote lead author of the study, Adit Ginde, MD from the University of Colorado, Denver.
For a Superior Vitamin D supplement ask me about Suzanne Sommers "Sip of Sunshine," Also contains Vitamin D3, Selenium, Patented GliSODin®, as well as Secalate™, Flower Pollen Extract-G40, Progallate™, Green Tea Extract (containing 50% EGCG) and B Vitamin Complex
More on Selenium
Higher blood levels of Selenium may reduce the incidence of skin cancer by about 60 per cent, according to a new study from Dutch and Australian researchers.
Writing in Cancer Epidemiology, Biomarkers & Prevention, the researchers report that the mineral was associated with reduced risks of both basal cell carcinoma and squamous cell carcinoma. In the US, over 1.5 million people are diagnosed with skin cancer very year. According to Cancer Research UK, a charity, over 76,000 cases of skin cancer were documented in 2005 but this is thought to under represent the problem.
“Relatively high serum Selenium levels of between 1.3 and 2.8 micromoles per liter were associated with approximately 60 decrease in subsequent tumor incidence of both BCC and SCC,” wrote the researchers.
Selenium is the Only Mineral that qualifies for an FDA Authorized Health Claim for General Cancer Reduction. (This Claim was sought by Dr. Joel Wallach BS., D.V.M., N.D.)
For More Info AskPharmacistKeith.com or AskParmacistKeith@live.com
Writing in Cancer Epidemiology, Biomarkers & Prevention, the researchers report that the mineral was associated with reduced risks of both basal cell carcinoma and squamous cell carcinoma. In the US, over 1.5 million people are diagnosed with skin cancer very year. According to Cancer Research UK, a charity, over 76,000 cases of skin cancer were documented in 2005 but this is thought to under represent the problem.
“Relatively high serum Selenium levels of between 1.3 and 2.8 micromoles per liter were associated with approximately 60 decrease in subsequent tumor incidence of both BCC and SCC,” wrote the researchers.
Selenium is the Only Mineral that qualifies for an FDA Authorized Health Claim for General Cancer Reduction. (This Claim was sought by Dr. Joel Wallach BS., D.V.M., N.D.)
For More Info AskPharmacistKeith.com or AskParmacistKeith@live.com
Vitamin D
Vitamin D Deficiency Could Increase Hip Fracture Risk Dramatically
US Researchers have concluded lower blood concentrations of Vitamin D increase the likelihood of hip fracture among menopausal women by up to 70%.
The University of Pennsylvania School of Medicine researchers concluded those women who had hip fractures had lower blood levels of Vitamin D.
“In our prospective, nested case-control study, we found that women with the lowest 25 (OH) Vitamin D concentrations (47.6 nmol/L) at study entry had a significantly greater increased risk for subsequent hip fracture during the next seven years than did women with the highest concentrations (70.7 nmol/L), “ The researchers wrote.
view link
askpharmacistkeith@live.com
US Researchers have concluded lower blood concentrations of Vitamin D increase the likelihood of hip fracture among menopausal women by up to 70%.
The University of Pennsylvania School of Medicine researchers concluded those women who had hip fractures had lower blood levels of Vitamin D.
“In our prospective, nested case-control study, we found that women with the lowest 25 (OH) Vitamin D concentrations (47.6 nmol/L) at study entry had a significantly greater increased risk for subsequent hip fracture during the next seven years than did women with the highest concentrations (70.7 nmol/L), “ The researchers wrote.
view link
askpharmacistkeith@live.com
Selenium Cancer Facts
In 1996 in the medical journal JAMA a study was published. Patients where given 250 mcg of selenium daily for 10 years. The subjects given the selenium had 71% fewer esophageal cancer, 60% fewer prostate cancer, 64% colorectal cancer, 48% fewer lung cancer, 50 to 80% less breast cancer (depending on the type).
Swine Flu
Well it is official. Seniors 65 and over are not on the guidelines for receiving the swine flu shot. We just recieved the guidelines from the CDC of who we will be able to give the Swine Flu shot to, here is a copy of what was sent:
Novel H1N1 Vaccination Recommendations
With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the US during the normally flu-free summer months and some uncertainty about what the upcoming flu season might bring, CDC's Advisory Committee on Immunization Practices has taken an important step in preparations for a voluntary novel H1N1 vaccination effort to counter a possibly severe upcoming flu season. On July 29, ACIP met to consider who should receive novel H1N1 vaccine when it becomes available.
Novel H1N1 Vaccine
Every flu season has the potential to cause a lot of illness, doctor’s visits, hospitalizations and deaths. CDC is concerned that the new H1N1 flu virus could result in a particularly severe flu season this year. Vaccines are the best tool we have to prevent influenza. CDC hopes that people will start to go out and get vaccinated against seasonal influenza as soon as vaccines become available at their doctor’s offices and in their communities (this may be as early as August for some). The seasonal flu vaccine is unlikely to provide protection against novel H1N1 influenza. However a novel H1N1 vaccine is currently in production and may be ready for the public in the fall. The novel H1N1 vaccine is not intended to replace the seasonal flu vaccine – it is intended to be used along-side seasonal flu vaccine.
CDC’s Advisory Committee on Immunization Practices (ACIP), a panel made up of medical and public health experts, met July 29, 2009, to make recommendations on who should receive the new H1N1 vaccine when it becomes available. While some issues are still unknown, such as how severe the virus will be during the fall and winter months, the ACIP considered several factors, including current disease patterns, populations most at-risk for severe illness based on current trends in illness, hospitalizations and deaths, how much vaccine is expected to be available, and the timing of vaccine availability.
The groups recommended to receive the novel H1N1 influenza vaccine include:
Pregnant women because they are at higher risk of complications and can potentially provide protection to infants who cannot be vaccinated;
Household contacts and caregivers for children younger than 6 months of age because younger infants are at higher risk of influenza-related complications and cannot be vaccinated. Vaccination of those in close contact with infants less than 6 months old might help protect infants by “cocooning” them from the virus;
Healthcare and emergency medical services personnel because infections among healthcare workers have been reported and this can be a potential source of infection for vulnerable patients. Also, increased absenteeism in this population could reduce healthcare system capacity;
All people from 6 months through 24 years of age
Children from 6 months through 18 years of age because we have seen many cases of novel H1N1 influenza in children and they are in close contact with each other in school and day care settings, which increases the likelihood of disease spread, and
Young adults 19 through 24 years of age because we have seen many cases of novel H1N1 influenza in these healthy young adults and they often live, work, and study in close proximity, and they are a frequently mobile population; and,
Persons aged 25 through 64 years who have health conditions associated with higher risk of medical complications from influenza.
We do not expect that there will be a shortage of novel H1N1 vaccine, but flu vaccine availability and demand can be unpredictable and there is some possibility that initially, the vaccine will be available in limited quantities. So, the ACIP also made recommendations regarding which people within the groups listed above should be prioritized if the vaccine is initially available in extremely limited quantities. For more information see the CDC press release CDC Advisors Make Recommendations for Use of Vaccine Against Novel H1N1.
Once the demand for vaccine for the prioritized groups has been met at the local level, programs and providers should also begin vaccinating everyone from the ages of 25 through 64 years. Current studies indicate that the risk for infection among persons age 65 or older is less than the risk for younger age groups. However, once vaccine demand among younger age groups has been met, programs and providers should offer vaccination to people 65 or older.
Did you notice the end:
Once the demand for vaccine for the prioritized groups has been met at the local level, programs and providers should also begin vaccinating everyone from the ages of 25 through 64 years. Current studies indicate that the risk for infection among persons age 65 or older is less than the risk for younger age groups. However, once vaccine demand among younger age groups has been met, programs and providers should offer vaccination to people 65 or older.
Their risk of infection may be lower but risk of DEATH is much higher.
view link
Novel H1N1 Vaccination Recommendations
With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the US during the normally flu-free summer months and some uncertainty about what the upcoming flu season might bring, CDC's Advisory Committee on Immunization Practices has taken an important step in preparations for a voluntary novel H1N1 vaccination effort to counter a possibly severe upcoming flu season. On July 29, ACIP met to consider who should receive novel H1N1 vaccine when it becomes available.
Novel H1N1 Vaccine
Every flu season has the potential to cause a lot of illness, doctor’s visits, hospitalizations and deaths. CDC is concerned that the new H1N1 flu virus could result in a particularly severe flu season this year. Vaccines are the best tool we have to prevent influenza. CDC hopes that people will start to go out and get vaccinated against seasonal influenza as soon as vaccines become available at their doctor’s offices and in their communities (this may be as early as August for some). The seasonal flu vaccine is unlikely to provide protection against novel H1N1 influenza. However a novel H1N1 vaccine is currently in production and may be ready for the public in the fall. The novel H1N1 vaccine is not intended to replace the seasonal flu vaccine – it is intended to be used along-side seasonal flu vaccine.
CDC’s Advisory Committee on Immunization Practices (ACIP), a panel made up of medical and public health experts, met July 29, 2009, to make recommendations on who should receive the new H1N1 vaccine when it becomes available. While some issues are still unknown, such as how severe the virus will be during the fall and winter months, the ACIP considered several factors, including current disease patterns, populations most at-risk for severe illness based on current trends in illness, hospitalizations and deaths, how much vaccine is expected to be available, and the timing of vaccine availability.
The groups recommended to receive the novel H1N1 influenza vaccine include:
Pregnant women because they are at higher risk of complications and can potentially provide protection to infants who cannot be vaccinated;
Household contacts and caregivers for children younger than 6 months of age because younger infants are at higher risk of influenza-related complications and cannot be vaccinated. Vaccination of those in close contact with infants less than 6 months old might help protect infants by “cocooning” them from the virus;
Healthcare and emergency medical services personnel because infections among healthcare workers have been reported and this can be a potential source of infection for vulnerable patients. Also, increased absenteeism in this population could reduce healthcare system capacity;
All people from 6 months through 24 years of age
Children from 6 months through 18 years of age because we have seen many cases of novel H1N1 influenza in children and they are in close contact with each other in school and day care settings, which increases the likelihood of disease spread, and
Young adults 19 through 24 years of age because we have seen many cases of novel H1N1 influenza in these healthy young adults and they often live, work, and study in close proximity, and they are a frequently mobile population; and,
Persons aged 25 through 64 years who have health conditions associated with higher risk of medical complications from influenza.
We do not expect that there will be a shortage of novel H1N1 vaccine, but flu vaccine availability and demand can be unpredictable and there is some possibility that initially, the vaccine will be available in limited quantities. So, the ACIP also made recommendations regarding which people within the groups listed above should be prioritized if the vaccine is initially available in extremely limited quantities. For more information see the CDC press release CDC Advisors Make Recommendations for Use of Vaccine Against Novel H1N1.
Once the demand for vaccine for the prioritized groups has been met at the local level, programs and providers should also begin vaccinating everyone from the ages of 25 through 64 years. Current studies indicate that the risk for infection among persons age 65 or older is less than the risk for younger age groups. However, once vaccine demand among younger age groups has been met, programs and providers should offer vaccination to people 65 or older.
Did you notice the end:
Once the demand for vaccine for the prioritized groups has been met at the local level, programs and providers should also begin vaccinating everyone from the ages of 25 through 64 years. Current studies indicate that the risk for infection among persons age 65 or older is less than the risk for younger age groups. However, once vaccine demand among younger age groups has been met, programs and providers should offer vaccination to people 65 or older.
Their risk of infection may be lower but risk of DEATH is much higher.
view link
